Open house rebate agreements Abatacept, ATC L04AA24
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Abatacept, ATC L04AA24
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
30 / 100
Facteurs de risque
No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.
The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Non-exclusive rebate agreements for Abatacept (ATC L04AA24) as per § 130a Abs. 8 SGB V
- Standardized contract terms, not individually negotiable
Afficher le résumé complet
Open-house model for non-exclusive rebate agreements on Abatacept (ATC L04AA24) by AOK Bayern. Any eligible pharmaceutical company can conclude a standard contract without competitive selection. Contract runs from 01 July 2026 to 30 June 2028. Rolling entry with monthly cutoffs; final deadline for contract conclusion is 03 May 2028. No estimated value or volume is provided.
Risques
No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.
The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Contract and annex must be signed by an authorized representative (proof of authority required via commercial register extract or power of attorney)
Eligibility
- Only pharmaceutical companies are eligible to participate
Administrative
- Must submit a signed declaration of reliability
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open house rebate agreements Abatacept, ATC L04AA24
Non-exclusive rebate agreement for the active substance Abatacept. The contract is a standard, non-negotiable agreement offered to all interested pharmaceutical companies meeting eligibility criteria. The contract can be terminated with one month's notice. It automatically becomes void if a nationwide or region-specific rebate contract for the same substance is concluded via an open procedure.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Abatacept, ATC L04AA24
Description TED originale
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Détails de la procédure
- Date de publication
- 17 May 2026
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 336029-2026
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
30 / 100
Facteurs de risque
No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.
The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications